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Mitomycin C (MMC) is a potent antitumour agent that forms a covalent bond with the 2-amino group of
selected guanines in the minor groove of double-stranded DNA following intracellular reduction of its
quinone ring and opening of its aziridine moiety. At some 5′-CG-3′ (CpG) steps the resulting
monofunctional adduct can evolve towards a more deleterious bifunctional lesion, which is known as an
interstrand crosslink (ICL). MMC reactivity is enhanced when the cytosine bases are methylated (5 MC)
and decreased when they are replaced with 5-F-cytosine (5FC) whereas the stereochemical preference of
alkylation changes upon decarbamoylation. We have studied three duplex oligonucleotides of general
formula d(CGATAAXGCTAACG) in which X stands for C, 5MC or 5FC. Using a combination of
molecular dynamics simulations in aqueous solution, quantum mechanics and continuum electrostatics,
we have been able to (i) obtain a large series of snapshots that facilitate an understanding in atomic detail
of the distinct stereochemistry of monoadduct and ICL formation by MMC and its decarbamoylated
analogue, (ii) provide an explanation for the altered reactivity of MMC towards DNA molecules
containing 5MC or 5FC, and (iii) show the distinct accommodation in the DNA minor groove of the
different covalent modiﬁcations, particularly the most cytotoxic C1α and C1β ICLs.
Introduction
Mitomycin C (MMC) was discovered as a potent anticancer anti-
biotic produced by Streptomyces caespitosus1 and is biosyntheti-
cally obtained nowadays from fermentation cultures of S.
lavendulae because of the challenge that its total synthesis still
represents.2 MMC’s broad spectrum of activity against solid
tumours was shown to be primarily due to its potent inhibition
of DNA replication mostly because of its ability to crosslink the
complementary strands of the double helix3 speciﬁcally at 5′-
CG-3′ (CpG) steps4,5 in hypoxic cells. Nonetheless, the major
product upon reaction of MMC with DNA is actually the
monofunctional adduct N2-(2′′β,7′′-diaminomitosen-l′′α-yl)-2′-
deoxyguanosine6 that is formed upon covalent bond formation
with the exocyclic amino group of guanine at position 2 of the
purine ring in just one strand.7
In clinical practice since the 1970’s, MMC is intravesically
instilled in the chemotherapy of superﬁcial bladder tumours8 and
used as topical adjunctive therapy in various ocular surgeries to
inhibit the wound healing response and reduce scarring.9 MMC is
also used parenterally, in combination with other approved drugs,
in the therapy of disseminated adenocarcinomas of the stomach or
pancreas and as palliative treatment of these malignancies when
other modalities have failed.10 It is noteworthy that hypersensitiv-
ity to MMC is a hallmark of cells deﬁcient in one or more of the
proteins involved in homologous recombination repair such as
Mus81,11 XPG,12 Pir51,13 Brca1,14 or the Partner and Localizer
of Brca2 (PalB2).15 Interestingly, biallelic inactivating mutations
in the gene encoding this latter protein were recently shown to
underlie the robust activity of MMC observed in nude mice xeno-
grafted with a gemcitabine-resistant human pancreatic cancer as
well as the dramatically favourable response attained in the
patient from whom the tumour had been resected upon treatment
with this drug.16 Moreover, sensitivity to MMC has been used to
classify Fanconi anemia (FA) patients into different complemen-
tation groups,17 can still be used for diagnostic purposes in vitro18
†Electronic supplementary information (ESI) available: Additional
bonded and nonbonded parameters for drugs and modiﬁed bases, four
additional ﬁgures and a scheme representing the different molecular
complexes and techniques employed during the study of the reactions
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and has been instrumental to delineate the so-called FA/BRCA
pathway of the DNA damage response.19
The deceptively “simple” structure of MMC (Scheme 1) pos-
sesses four contiguous stereogenic carbons and economically
packs in a constrained architecture (i) a quinone-containing pyr-
roloindole skeleton, (ii) a methoxy group, (iii) an aziridine ring,
and (iv) a carbamate moiety.2 The aziridine at C1 and the carba-
mate at C10 are critical to its biological activity because they
constitute two masked alkylating functionalities. Indeed, MMC
itself is remarkably unreactive toward DNA at pH 7–83 but
efﬁcient alkylation of this macromolecule is observed following
enzymatic, electrochemical or chemical reduction,20 hence its
greater cytotoxicity under hypoxic conditions and the recog-
nition of MMC as the ﬁrst bioreductive (and bifunctional) alky-
lating agent.3,21 Two-electron reduction of the quinone ring of
MMC facilitates methoxide elimination from position 9a, for-
mation of a leuco-aziridinomitosene and opening of the aziridine
ring to provide the extended quinone methide that is the initial
alkylating entity leading to a DNA monoadduct with a guanine
(G ̲) in the minor groove.7,20 At a CpG ̲ step, the second alkylating
centre of MMC is the iminium ion that forms upon the reverse
Michael elimination of carbamic acid at C10 from the mono-
adduct. It is at this position then that MMC can undergo a
second nucleophilic attack either by a water molecule (to yield a
C10-decarbamoylated monoadduct)7 or, exclusively at CpG
steps, by the 2-amino group of the guanine in the opposite strand
(i.e. the G pairing with the cytosine in CpG ̲) thus giving rise to
the ICL (Scheme 1). This DNA lesion represents a major threat
to cell viability because it is highly effective in blocking replica-
tion and transcription forks.22 The fact that, under standard con-
ditions, alkylation at C10 always follows reaction at C1 explains
why ICLs in duplex DNA are observed only at CpG sites. Intra-
strand crosslinks at GpG steps,23 as well as other non-cytotoxic
monoadducts that arise from the MMC metabolite
2,7-diaminomitosene,24 have also been characterized but will not
be dealt with in the present work.
The nature of the base on the 3′-side of the guanine that is
alkylated by MMC (G ̲) plays a relatively minor role in site selec-
tivity, with reactivity decreasing in the order CG̲C > CG ̲T >
CG ̲G > CG ̲A5 reportedly due to the possibility of the 3′-pyrimi-
dine assisting in the removal of the proton from the 2-amino
group of guanine during the nucleophilic attack.25 On the other
hand, the preference of MMC for different dinucleotide steps,
quantiﬁed in terms of yields and reaction rates with guanine,
follows the order CpG ̲ > GpG ̲ ≫ TpG ̲ ≈ ApG ̲.5 The presumed
involvement of the 2-amino group of a second guanine in the
clear enhancement observed at the former two steps, and particu-
larly at the CpG step, through a putative hydrogen bond with the
carbamate oxygen attached to C10 (OM) in activated MMC was
indirectly supported by the demonstration that replacement of the
guanine in the complementary strand with hypoxanthine (as
found in deoxyinosine) resulted in much lower reactivity5 and
also by the ﬁnding that MMC analogues lacking this OM did
not show any selectivity towards CpG steps.26 Conversely, 5-
methylation of the cytosines making up this site was seen to
result in a ∼2-fold increase in the reactivity of the synthetic
oligodeoxynucleotides thus modiﬁed. This effect was attributed
to either electronic or steric factors, namely, either enhanced
nucleophilicity of the 2-amino group of guanine or greater acces-
sibility of the amino group due to a local conformational
change.27 Later work using a 162-bp DNA fragment in which all
cytosines had been replaced with either 5-methyl-cytosine
(5MC) or 5-F-cytosine (5FC) conﬁrmed this increased reactivity
for CpG sites containing 5MC and further showed that the oppo-
site was true when the CpG site contained 5FC in lieu of C. The
respective stimulatory and inhibitory effects of 5MC and 5FC
were shown to be selective to the G that is paired with the
modiﬁed pyrimidine. In this case, the explanation put forward to
Scheme 1 Reaction pathways leading to the formation of α-MMC–DNA and β-DMC–DNA monoadducts and their corresponding bisadducts or
interstrand crosslinks (ICL) of opposite stereochemistry. The DNA-alkylating functionalities of MMC and DMC are unmasked by reductive activation.
1544 | Org. Biomol. Chem., 2012, 10, 1543–1552 This journal is © The Royal Society of Chemistry 2012
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account for these reactivities, which were said to correlate with
the Hammett σ constants, was that the electron-donating effect of
the 5-methyl substituent of the cytosine was transmitted to
guanine through H-bonding of the 5MC:G base pair.28 On the
basis of density functional calculations on simpliﬁed model
systems it was later proposed that one of the H-bonding hydro-
gens from the 2-amino position of the attacking G would be tem-
porarily transferred to the cytosine oxygen with which it pairs to
facilitate the reaction29 but no further support for this hypothesis
has been obtained.
It is then clear that MMC is a prodrug unable to bind to DNA
unless it has been reduced. But precisely because its reductively
activated forms are too reactive and short-lived for binding
studies,7,21 examination of the noncovalent association of this
drug or its active metabolite(s) with different double helices has
not been feasible. Furthermore, the structural work has been very
limited despite the early use of CPK6 and computer-generated
models,4,30,31 which only in a few instances were built making
use of NMR-derived information on the monoalkylated
product.32,33 Thus, to date and to the best of our knowledge,
only the solution NMR structure of the d(ICACG̲TCIT)·
d(ACGACGTGC) duplex containing the major MMC mono-
adduct at the underlined guanine32 is deposited in the public
domain (Nucleic Acid Database34 entry 199D) and models of an
MMC ICL have been reported only for the self-complementary
d(GCATCG ̲ATGC)2 decamer4 and d(TACG ̲TA)2 hexamer,33
which do not represent optimal bonding sites. A common feature
of all of these models is the proposal that the N2-guanine-
bonded MMC molecule ﬁts snugly into the minor groove
without appreciable perturbation of the DNA structure but none
of them provides information about the precovalent complex(es)
or the rationale for the stereochemistry of the drug-G covalent
bond. In fact, the current paradigm holds that the preference for
the CpG site is a consequence of the hydrogen bond between the
carbamate oxygen of the MMC activated species and the amino
group on the guanine of the nonbonding strand, a proposal that
appears to be corroborated by the NMR structural work on the
monoadduct.32 A role for the carbonyl oxygen in this recog-
nition was ruled out in view of the apparently similar bonding
patterns obtained for MMC and 10-decarbamoylmitomycin C
(DMC, Scheme 1) in early λ exonuclease stop assays31 and also
by the largely decreased sequence selectivity displayed by MMC
derivatives bearing a halogen atom in place of the carbamoyl
group.26 Nonetheless, although DMC was initially regarded as a
less active monofunctional derivative of MMC35 later work
showed it to produce more adducts and be more cytotoxic than
MMC in certain cells, including FA ﬁbroblasts, and to give rise
to bisadducts.36,37 Strikingly, however, the chirality of the mito-
sene linkage between DMC and the amino group of guanine was
shown to be largely C1-β rather than the C1-α that is overwhel-
mingly observed for MMC, both in the more readily formed
monoadducts and in the less frequent ICLs. Therefore the
current paradigm cannot account for the opposite stereo-
chemistry of the major DNA adducts produced in mammalian
cells by MMC and DMC and for the differential sensitivity of
FA cells to these drugs.37
To obtain information in atomic detail about the mechanism
of CpG recognition and bonding by MMC and DMC, we
have focused on a DNA double helix of sequence
d(CGATAACGCTAACG) in one strand and the complementary
sequence in the opposite strand. Using this 14mer, which
embeds a high-afﬁnity CGC site for mono- and bis-alkylation in
the middle region, we have simulated in a continuous fashion all
the steps of the reaction leading from the initial precovalent com-
plexes to the ﬁnal (and distinct) ICLs through prior formation of
the respective monoadducts. Bond making and breaking during
the molecular dynamics (MD) simulations was made possible by
coupling a quantum mechanical (QM) function to a classical
molecular mechanics (MM) potential, as recently implemented38
in the popular AMBER suite of programmes (http://ambermd.
org/). The main advantage of a hybrid approach involving MD
and QM for the solvated drug–DNA complexes over studies that
focus on simpliﬁed model systems is that changes in atom con-
nectivities and charge redistributions are performed in a dynamic
context that realistically allows reorganization of both solutes
and water molecules through the whole procedure. Besides, in
order to ﬁnd a rationale to the observation that MMC–DNA
monoadduct formation (and therefore subsequent interstrand
crosslinking) is altered at CpG sequences bearing cytosine
modiﬁcations,27,28 simulations were also performed on similar
DNA 14mers in which the cytosines making up the central CpG
step contained either a methyl group or a ﬂuorine atom at pos-
ition 5. For comparison purposes and completeness, the three
oligodeoxynucleotides studied as targets for MMC and DMC
were also simulated in their free states. The trajectories were ana-
lyzed in terms of structural parameters, suitable geometries for
nucleophilic attack, molecular electrostatic potentials and
solvent-corrected binding energies.
Materials and methods
Geometries, AMBER parameters and charges for the
non-standard residues
The X-ray crystal structure of MMC39 was the starting point for
model building this prodrug, as well as DMC and their corre-
sponding reactive intermediates. The geometries of MMC,
DMC, activated MMC (both as a hemiquinone methide and as a
carbocation, MMC+), activated DMC (as a carbocation, DMC+),
reduced MMC–G ̲ monoadduct, reduced DMC–G ̲ monoadduct,
activated MMC–G̲ monoadduct, activated DMC–G ̲ monoadduct,
G–MMC–G̲ and G–DMC–G̲ bisadducts, 5FC, and 5MC were
ﬁrst reﬁned by means of the semiempirical QM program
MOPAC200940 using the AM1 Hamiltonian41 and PRECISE
stopping criteria, and further optimized using the restricted
Hartree–Fock (RHF) method and a 6-31G(d) basis set, as
implemented in the ab initio quantum chemistry program Gaus-
sian03.42 The modiﬁed nucleic bases incorporated a methyl
group on either N9 (G) or N1 (C) in place of the deoxyribose
ring. For each molecular system the calculated wave function
was then used to derive electrostatic potential-derived (ESP)
charges employing the RESP methodology.43 Point charges for
deoxyribose and phosphate atoms in the modiﬁed nucleotides
were restrained to the values these atoms have in the parmbsc0
AMBER force ﬁeld,44 which includes corrections for an
improved description of DNA conformations on a multinano-
second time scale.45 Additional bonded and nonbonded
parameters for drugs and modiﬁed bases are reported in the ESI.
This journal is © The Royal Society of Chemistry 2012 Org. Biomol. Chem., 2012, 10, 1543–1552 | 1545
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Construction of the oligodeoxynucleotides
An initial model for the free 14mer of sequence d-
(CGATAACGCTAACG)· d(CGTTAGCGTTATCG) was built
using the nucgen module in AMBER and optimized parameters
for B-DNA.46 Terminal G:C base-pairs on both sides of the A,T-
rich regions were used to avoid fraying of the double helix.47
Replacement of the cytosine base with either 5MC or 5FC in the
central CpG step provided initial models for the modiﬁed oligo-
nucleotides. The MMC-N2(G ̲) monoadduct found in NDB entry
199D32 was used as a template for model building the precova-
lent intermediates by placing the activated MMC molecule in a
similar location and avoiding the steric clash upon bond removal
by steepest descent energy minimization.
Molecular dynamics simulations
Each molecular system was immersed in a truncated octahedron
of TIP3P water molecules48 and neutralized by addition of the
appropriate number of Na+ ions49 at random locations. The stan-
dard MD simulations were run using the pmemd module in the
AMBER 11 suite of programs. Periodic boundary conditions
were applied and electrostatic interactions were treated using the
smooth particle mesh Ewald method50 with a grid spacing of
1 Å. The cutoff distance for the non-bonded interactions was
9 Å. The SHAKE algorithm51 was applied to all bonds involving
hydrogens and an integration step of 2.0 fs was used throughout.
Solvent molecules and counterions were relaxed by energy mini-
mization and allowed to redistribute around the positionally
restrained solute (25 kcal mol−1 Å−2) during 50 ps of MD at
constant temperature (300 K) and pressure (1 atm), essentially as
described previously.52 These initial harmonic restraints were
gradually reduced in a series of progressive energy minimiz-
ations until they were completely removed. The resulting
systems were heated from 100 to 300 K over 20 ps, equilibrated
at 300 K for 1 ns in the absence of any restraints and further
simulated under the same conditions up to a total time of 10–20
ns during which system coordinates were collected every 20 ps
for further analysis.
Hybrid QM/MM calculations
The system was partitioned into two distinct parts: a QM region
deﬁned by the iqmatoms keyword that consisted of the atoms rel-
evant for the speciﬁc bonding reaction being studied and their
immediate surroundings, and an MM region with all the remain-
ing atoms, including the solvent molecules and the counterions.
The AM1 Hamiltonian41 and full electrostatic interactions
between the QM charge density (expanded in a STO-6G
minimal basis set) and the standard RESP/6-31G(d) point
charges of the MM atoms were used,38 as implemented in the
sander module of AMBER 11. In the case of the precovalent
complexes, the QM region included the reactive MMC and
DMC derivatives plus the whole CpG step (to ascertain any
possible differences involving the cytosines) whereas in the
study of ICL formation, the QM region included the drug-
G8 monoadduct plus the second guanine (G22) in the opposite
strand. Reaction coordinates were speciﬁed for covalent bond
formation, ﬁrst between N2 of G8 and C1 of MMC+ or DMC+
and then between N2 of G22 and C10 in the monoadduct, using
the steered MD procedure implemented in sander.53 In brief, the
N–C distance between the two atoms to be bonded was shor-
tened linearly from its current value in the precovalent complex
to a target value of 1.35 Å over 5 ps using a harmonic restraint
of 1000 kcal mol−1 Å−2 while all other variables were free to
change. During the QM/MM part of the MD simulation SHAKE
(keyword qmshake) was turned off and the integration step was
reduced to 0.5 fs. Upon achievement of the ﬁnal state, the
AMBER topology ﬁle was updated with the new bond and atom
type deﬁnitions, and a short energy minimization using the
redeﬁned connectivities and point charges allowed this geometry
to be optimized in the MM force ﬁeld prior to continuing the
standard MD simulation. A scheme depicting the different MD
and QM/MM phases of the whole study is given in the ESI.†
Analysis of the molecular dynamics trajectories and electrostatic
energy calculations
Three-dimensional structures and trajectories were visually
inspected using the computer graphics program PyMOL.54
Interatomic distances and angles, as well as root-mean-square
deviations (rmsd) from a given structure, were monitored using
the ptraj module in AMBER. The DNA conformational and
helical parameters were analyzed by means of the program
Curves+.55 Molecular electrostatic potentials (MEP) around the
low-dielectric solutes (ε = 1) were calculated by treating the sur-
rounding solvent as a continuous high-dielectric medium
(ε = 78.5) and solving the non-linear Poisson–Boltzmann (PB)
equation by means of a ﬁnite difference method as implemented
in program DelPhi56 version 4 and described in more detail else-
where.52,57 To highlight the most dissimilar MEP regions
between any two DNA molecules, their central CGC triplets
were best-ﬁt superimposed and identical grids were calculated
for both using the VSDMIP plugin.58 The energy value at each
grid point for one molecule was then subtracted from the value
calculated at the same grid point for the other molecule, as
reported previously,59 and the difference map was visualized in
PyMOL.
MM–GBSA binding energy calculations
The binding free energy (ΔGbinding) between a reactive inter-
mediate of MMC (MMC+) and a given DNA oligonucleotide
(standard, 5MC-DNA or 5FC-DNA) was calculated as:
ΔGbinding ¼ kGDNAMMCþðiÞ  GDNAðiÞ  GMMCþðiÞli ð1Þ
where 〈〉i denotes an ensemble average over i snapshots taken
from the MD trajectories of the precovalent complexes. For com-
parison purposes we took 150 snapshots from 3.0 ns of each
simulation during which MMC+ was similarly oriented in the
minor groove of the three complexes studied. The Gi values for
each species were calculated using the following energy
decomposition scheme, which is implemented in the
MM–GBSA method within AMBER 11 (script mm_pbsa.pl):60
G ¼ Egas þ Gsol  TS
1546 | Org. Biomol. Chem., 2012, 10, 1543–1552 This journal is © The Royal Society of Chemistry 2012
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Egas ¼ Ebond þ Eangle þ Etorsion þ Eele þ Evdw
Gsol ¼ GGB þ Gnonpolar
Gnonpolar ¼ γSASA
Egas is the gas phase energy, calculated using the AMBER
force ﬁeld, which encompasses internal energies from bond
lengths (Ebond), valence angles (Eangle) and torsional angles
(Etorsion), as well as coulombic (Eele) and van der Waals (Evdw)
non-bonded contributions calculated with no cutoff. In the case
of individual trajectories, as in the present case, the contribution
of the internal energies to ΔGbinding amounts to zero. The sol-
vation free energy, Gsol, was decomposed into polar and non-
polar contributions; the former (GGB) was calculated by solving
the generalized Born (GB) equation61 using dielectric constants
of 1 and 78.5 for solute and solvent, respectively, whereas the
latter, Gnonpolar, which is due to due to cavity formation and van
der Waals interactions between the solute and the solvent, was
estimated from the nonpolar solvent accessible surface area
(SASA)62 using 1.4 Å as the water probe radius and a value of
0.005 kcal mol−1 Å−2 for the surface tension constant γ. T and S
are the temperature and the total solute entropy but this term,
which is cumbersome to compute and most likely similar for the
three DNA–MMC complexes under study, was obviated in our
approximation to the binding free energy differences.63
Results and discussion
Drug conformation and orientation in the precovalent complexes
The MD simulation of the initial complex containing the stan-
dard oligodeoxynucleotide and an activated MMC molecule
(MMC+) in the minor groove of the central region corresponding
to the C7:G22/G8:C21 base-pair step (Scheme 2) revealed that
the hydrogen bond between the carbamate OM atom and the
exocyclic amino group of G22 was not particularly stable in the
face of competition with water molecules. This hydrogen bond
was reported for the monoadduct structure solved by NMR spec-
troscopy32 and presumed to dominate sequence recognition in
the precovalent complex as well. However, in addition to the
weak character and short life of this interaction (Fig. 1), we also
noted that this orientation of the drug in the minor groove was
incompatible with a nucleophilic attack by N2(G8) on the α face
of the MMC tetrahydropyrrole ring.
This unexpected result led us to reconsider the conformation
of MMC+ inside the minor groove and explore alternative
hydrogen bonding modes. In our lab, previous conformational
studies on MMC+ in the gas phase (data not shown) had revealed
a preferred geometry that involved formation of an internal
hydrogen bond between the phenol group at C8 and oxygen
OM, and this conformer was also detected in aqueous solution
when the dynamic behaviour of MMC+ was simulated (Sup-
plementary Figure S1†). Besides, additional QM work on a CpG
dinucleotide model system had shown that, using this confor-
mation, a reaction coordinate deﬁned to create the covalent bond
leading to the α monoadduct could be accomplished. Interest-
ingly, when this particular MMC+ conformer was docked into
the oligo’s minor groove region comprising C7:G22/G8:C21, we
realized that a good hydrogen bond with the amino group of
G22 could actually be established by the carbonyl oxygen (OC)
instead of OM, as in the previous case. Therefore OC, rather
than facing the solvent as in the former simulation, was directed
towards the strand opposite to that being alkylated (Fig. 1). The
MD trajectory of this new complex allowed us to see that this
binding pose remained stable and not only provided a distance
between C1 of MMC+ and N2(G8) that was suitable for nucleo-
philic attack, i.e. ≤4 Å (Fig. 1), but also allowed an approach on
the ring face opposite to that of the primary amino group at C2
(Scheme 1). This particular orientation was additionally stabil-
ized by two hydrogen bonds: a strong one between the phenolic
O5 and phosphate OP1 oxygens, and another between the sp2
N2(G8) and the sp3 nitrogen of the primary amino group at pos-
ition 2 of the activated drug. This hydrogen-bonding anchoring,
which is maintained for virtually the whole simulation (Sup-
plementary Figure S2†), contributes to placing the mitosene ring
system in an asymmetric position within the minor groove
so that only one face is in van der Waals contact with the sugar-
phosphate backbone of the unmodiﬁed strand whereas the other
one remains exposed to the aqueous milieu.
Scheme 2 Simpliﬁed diagram representing the alignment of MMC+ in
the minor groove of the DNA duplex central region showing the num-
bering of the base pairs involved in adduct formation.
Fig. 1 Left: Details of representative MD snapshots from the MD
simulations showing the distinct orientations of MMC+ (top) and DMC+
(bottom) in the DNA minor groove prior to nucleophilic attack by the 2-
amino group of G8. Drug and DNA carbon atoms are coloured in cyan
and green, respectively. Right, from top to bottom: Time evolution of
N2(G8)–C1(drug) and N2(G8)–N2(drug) distances for MMC+ (blue) and
DMC+ (red), and the angle for attack.
This journal is © The Royal Society of Chemistry 2012 Org. Biomol. Chem., 2012, 10, 1543–1552 | 1547
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In DMC, on the other hand, a hydroxymethyl substituent
replaces the methyl carbamate moiety of MMC. Consequently,
only one oxygen (OM) is present in the drug’s side chain avail-
able for hydrogen-bonding to the DNA. When DMC+ was
docked in the minor groove region of the C7:G22/G8:C21 base-
pair step similarly to MMC+ and the resulting complex was
simulated using MD, we noticed that OM could indeed accept a
hydrogen bond from the amino group of G22 (Fig. 1) but the
half-life of this interaction was shorter because of exchange with
solvent molecules in the nanosecond timescale (data not shown).
Nonetheless, this hydrogen bond largely contributed to placing
DMC+ in an orientation such that attack by N2(G8) would occur
preferentially, although not exclusively, on the β face of the
drug’s tetrahydropyrrole ring (Fig. 1). In this complex, the acti-
vated drug is roughly equidistant from both DNA strands and no
direct hydrogen bond with any phosphate group is detected.
Taken together, these results strongly suggest that the very dis-
tinct relative occurrence of α and β DNA monoadducts formed
in the presence of MMC and DMC36,37 is largely dictated by the
nature of the hydrogen bond involving either the carbamate or
the hydroxyl oxygen in the activated drugs and the amino group
of the guanine in the unmodiﬁed strand that is complementary to
the cytosine in the CpG step undergoing G-alkylation. The fact
that DMC and MMC show opposite stereochemical preferences
supports the roles that we assign to the carbonyl oxygen, OC,
which is only present in the former compound, and to OM,
which is present in both MMC (as part of the carbamate) and
DMC (as a hydroxyl). Altogether, the drug–DNA hydrogen
bonds involving these oxygens crucially determine the proposed
near-attack conformations and binding modes for MMC and
DMC, which are distinct and can be distinguished by monitoring
an improper dihedral angle for the incoming 2-amino group rela-
tive to the mitosene tetrahydropyrrole ring (Fig. 1).
Precovalent complexes between MMC+ and DNA containing
modiﬁed cytosines
Once the putative binding mode for MMC+ in the minor groove
of the central C7:G22/G8:C21 region was identiﬁed, we carried
out similar MD simulations with the oligodeoxynucleotides in
which C7 and C21 had been replaced with either 5MC or 5FC.
When we calculated the binding energy (ΔGbinding) between
MMC+ and the central CGC triplet using the MM–GBSA
method, we found that, relative to the standard oligonucleotide,
it was more favourable for the duplex containing 5MC whereas
it was signiﬁcantly decreased in the duplex containing 5FC
(−11.2 ± 3.5, −12.1 ± 3.5, and −6.9 ± 1.5 kcal mol−1, respect-
ively). Furthermore, an energy decomposition analysis (Fig. 2)
showed that, in both cases, the base providing the largest differ-
ences is precisely C21, i.e. the cytosine complementary to the
guanine undergoing alkylation, which displays an improved
interaction with the drug when it is methylated. Our theoretical
result that C21, rather than C9, is largely responsible for these
differences in ΔGbinding is in very good agreement with exper-
imental evidence showing the prevalence of the 5MC that is
paired to the alkylated guanine over that placed 5′ to it in the
same strand.64
Since the major energy component appeared to be electrostatic
we decided to explore the MEP generated in the minor groove of
this central region in the three oligonucleotides studied. To facili-
tate comparisons we also calculated and displayed the MEP
differences relative to the duplex containing standard cytosines
(Fig. 3). It can be seen that signiﬁcant differences do arise in the
minor groove (and also between the stacked bases), despite the
fact that the structural changes are located in the major groove.
This type of observation has been used earlier to account for
differences in the binding preferences of several bisintercalators
(e.g. ref. 52 and 59) and can be used here to provide a rationale
to the experimental ﬁnding that cytosine methylation enhances
the rate of DNA alkylation by MMC whereas the opposite is true
if C is replaced with 5FC.27,28 Our interpretation is that the more
negative MEP found in the drug-binding region when the cyto-
sines in the CpG step are methylated facilitates and strengthens
the electrostatic interaction with the positively charged alkylating
species.
DNA conformational parameters
To complete the study of the precovalent complexes, we exam-
ined their geometrical properties and compared them to those of
free DNA, 5MC-DNA and 5FC-DNA. The very similar DNA
conformations were well maintained during the course of the
MD simulations (data not shown) and only subtle differences
involving the critical G8pC9 step were observed. In particular,
analysis of the stacking geometry between neighboring G8:C21
and C9:G20 base-pairs revealed a signiﬁcant displacement
towards negative tilt values relative to free DNA (Fig. 4) when
MMC+ is located in the DNA minor groove in a suitable position
Fig. 2 Calculated binding energies between MMC+ and individual
DNA bases in the precovalent complexes formed with standard DNA,
5MC-DNA and 5FC-DNA.
Fig. 3 Close-up view of the CpG region where MMC binds and
display of the difference in molecular electrostatic potential (MEP)
between 5MC-DNA and standard DNA (contoured at −5 kcal mol−1).
Note the more negative character of the MEP around the O2 of both
methylated cytosines.
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for nucleophilic attack by N2(G8). This means that the angle
formed between these base-pairs needs to be opened towards the
unmodiﬁed DNA strand in order for the reaction to proceed.
Remarkably, this slightly distorted geometry is naturally present,
in the absence of bound drug, when C9 and C21 are methylated
and also, to a lesser extent, when C is replaced with 5FC. It is
therefore likely that this structural preorganization for MMC+
binding in the DNA containing the modiﬁed cytosines acts in
concert with the more negative MEP in the minor groove to
enhance alkylation by MMCwhen the 5 substituent is an electron-
donating methyl group. On the other hand, in the case of the DNA
containing 5FC in the central region, it seems that the less favour-
able electrostatic interaction with MMC+ prevails over the more
preorganized geometry to decrease drug binding to this site.
Formation and description of the MMC and DMC monoadducts
We used different snapshots from the MD trajectories of the
MMC+–DNA and DMC+–DNA precovalent complexes reported
above to start simulating the QM reaction coordinate that leads
to covalent bond formation between N2 of the attacking guanine
(G8) and C1 of the drugs by systematically reducing this dis-
tance using the hybrid QM/MM method. Interestingly, a consist-
ent pattern was found that revealed that the opposite α or β
stereochemistry at C1 of the resulting adduct (Schemes 1 and 2)
was entirely dependent on the conformation-driven positioning
of the activated drug in the DNA minor groove. Thus, in the
simulation involving MMC+, hydrogen-bonding of the drug’s
OC to N2(G22) determined formation of the C1α-monoadduct
whereas the C1β-stereoisomer was systematically obtained when
this hydrogen bond was lost. An identical result was obtained
when the same procedure was used on the precovalent (5MC)
DNA–MMC+ and (5FC)DNA–MMC+ complexes. The free
energy proﬁles for this step of the reaction, on the other hand,
showed no signiﬁcant differences among the three complexes
(Supplementary Fig. 2A†).
In the resulting MMC–DNA covalent intermediate N2(G8)
still bears two hydrogens, one of which (H21) can still be used to
pair with the complementary O2(C21) following relaxation of
the complex. But the extra H22 must be transferred to the amino
group of the bonded drug (Scheme 1) and, given the geometry
of the resulting adduct, this proton shuttle could only be effected
with the concourse of the nucleobase 3′ to the alkylated guanine,
in our case O2(C9). Nonetheless, simulation of these reactions
using the QM/MM method turned out to be unfeasible. We then
realized that in the precovalent complexes reported above for
both MMC+ and DMC+ the sp2-hybridized N2(G8) was close
not only to C1 of the drugs but even more so to the sp3-hybri-
dized amino group at C2, with which it could actually establish a
good hydrogen bond. In fact, both sets of interatomic distances
were found to be strictly correlated during the MD simulations
(Fig. 1), which suggests that transfer of H22 to N2(MMC+) or
N2(DMC+) could be concomitant with the formation of the
C1–N2(G8) bond, but this alternative reaction pathway was not
explored further.
The structures of the resulting MMC–DNA and DMC–DNA
complexes containing, respectively, the α- and β-monoadducts
were relaxed upon relocation of the extra H22 on N2(G8) to the
amino group of the bonded drug and equilibrated for 10 ns of
unrestrained MD simulations. The MMC–DNA complex faith-
fully reproduced the major features of the models originally
reﬁned on the basis of NOE intensities and deposited in the
NDB with code 199D,32 despite differences in base composition
and sequence on both sides of the central CpG step and the fact
that the NMR solution structure considered a benzoquinone ring
in MMC rather than the hydroquinone present in our model and
necessary for evolution towards a bisadduct. Most noteworthy
are (i) the absence of signiﬁcant deviations in helical parameters
with respect to free DNA (data not shown), (ii) a slight widening
of the minor groove (Fig. 5) where the covalently bonded drug
remains in an off-centre location despite the loss of the
O5–OP1 hydrogen bond, and (iii) alternative orientations for the
carbamate side chain of MMC.
In the case of the DMC β-adduct, the drug is lodged in a
slightly compressed minor groove (Fig. 5), where it interacts
simultaneously with the sugar-phosphate backbone of both
strands, and the hydroxyl group at C10 keeps its hydrogen-
bonding interaction with O2(T23).
Fig. 4 Distribution of tilt values at the G8pC9 step of the central CGC
triplet over the MD simulations of free (grey) standard DNA (top),
5MC-DNA (middle) and 5FC-DNA (bottom) and their respective preco-
valent complexes with MMC+ (black). No signiﬁcant differences were
observed at the C7pG8 step.
This journal is © The Royal Society of Chemistry 2012 Org. Biomol. Chem., 2012, 10, 1543–1552 | 1549
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From the above, it must be noted that a DMC–DNA complex
resulting from water-mediated decarbamoylation of DNA-
bonded MMC,36 which appears to be more abundant in cells
than the original adduct,37 is stereochemically identical (C1α) to
only one of the two monoadducts that readily originate from
direct attack of DMC to DNA (Scheme 1), although in this case
the C1β is obtained in a signiﬁcantly larger proportion.37
Interstrand crosslinking by DNA-bonded MMC and DMC at
the CpG step
Once the structures of the duplexes containing the α- and
β-monoadducts were equilibrated, we proceeded to remove the
carbamate (in the case of MMC) and the hydroxyl (in the case of
DMC) so as to generate the second alkylating species. After 10
ns of equilibration of these new complexes using standard MD,
we could observe that the separation between the exocyclic
N2(G22) and C10 of the drug ﬂuctuated less in the case of DMC
and remained close to 4 Å (Supplementary Fig. 3†), a suitable
distance for nucleophilic attack and similar to that reported
above for monoadduct formation. By switching to the QM/MM
method we shortened the N2–C10 distance so as to create the
second covalent bond and give rise to the corresponding bis-
adducts, which were equilibrated thereafter for 20 ns of unrest-
rained MD simulation.
Our results show that the DNA is able to accommodate this
dual covalent modiﬁcation (on G8 in one strand and G22 in the
opposite strand) undergoing minimal distortion only in the case
of the C1α-ICL, in agreement with early work that employed
MM exclusively.4 In this bis-adduct, the crosslinking mitosene
unit is settled in the minor groove of the CpG step in close
contact with the strand containing the second alkylated guanine;
the global structural parameters of the DNA molecule hardly
Fig. 5 a) Representative MMC–DNA α-monoadducts showing the two
most populated orientations of the drug in the minor groove depending
on whether the carbonyl oxygen of the drug’s carbamate group is hydro-
gen bonded to N2(G22) (left) or not (right). b) Representative
DMC–DNA β-monoadduct showing the hydrogen bond between the
drug’s hydroxyl and O2(T23). c) Widths of the minor groove in free
DNA and in the two types of adducts.
Fig. 6 Top: representative snapshots of the duplexes containing the
C1α (left, blue frame) and C1β (right, red frame) bis-adducts that cross-
link the two DNA strands. The DNA atoms are surrounded by a semi-
transparent van der Waals surface. Bottom: Distributions of base-pair
helical parameters (excluding both ends) in the duplexes containing the
C1α (blue) and C1β (red) ICL. Twist, tilt and roll are in degrees. Shift,
slide and rise are in Å. The vertical line represents the average for the
simulated drug-free DNA.
Fig. 7 Left: detail of the central region of the duplexes containing the
C1α (top, blue frame) and C1β (bottom, red frame) bis-adducts that
crosslink the two DNA strands, as seen from the major groove. Note the
loss of intrastrand stacking interactions at the central CpG step in the
C1β ICL. Right: Time evolution of rise (top), shift (middle) and roll
(bottom) parameters at the C7pG8 step during the MD simulations of
the bis-adducts. The pink horizontal line in each plot represents the
average value for drug-free DNA.
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change with respect to the drug-free duplex (Fig. 6). On the con-
trary, in the C1β-ICL, whose structure has not been reported yet
as far as we know, the mitosene unit is more equidistant to both
DNA strands but the rise, shift and roll parameters at the C7pG8
step signiﬁcantly deviate from the values in free DNA and this
causes a marked change in the distribution of these values
(Fig. 6). A more detailed view from the major groove is shown
in Fig. 7 where the loss of stacking interactions at this step can
be visually appreciated and also deduced from the increased rise
values that are monitored along the MD trajectory. The negative
shift is a consequence of the displacement of the drug-bonded
guanines into the minor groove whereas the correlated negative
roll indicates bending of the helix toward the minor groove, a
situation contrary to what is observed in DNA duplexes contain-
ing an adduct with the monofunctional antitumour tetrahydroiso-
quinolines trabectedin (Yondelis®) or PM01183, which have
been shown to bend the helix toward the major groove by intro-
ducing positive roll65,66 and can functionally mimic an ICL.67
Conclusions
The oligodeoxynucleotide used in the present study contains a
highly preferred CGC triplet site in the middle region for MMC
and DMC binding. Furthermore the initial monoadducts formed
with G8 can evolve towards an ICL by forming a second
covalent bond with G22 in the opposite strand. By simulating
each step of the reaction using a combination of MD and QM/
MM calculations, we have been able to obtain information in
atomic detail about the recognition events prior to monoadduct
formation as well as about the structural and electronic require-
ments that possibly account for the increased reactivity of MMC
towards CpG steps containing 5MC in place of cytosine. More-
over, we provide a possible explanation to the origin of the for-
mation of either C1α or C1β monoadducts depending on the
drug–DNA hydrogen bonds that are established in the precova-
lent DNA–MMC+ and DNA–DMC+ complexes. According to
our ﬁndings, formation of a hydrogen bond between the carba-
mate oxygen of activated MMC and the guanine in the strand
opposite to that containing the G that undergoes the ﬁrst alky-
lation reaction appears to favour formation of the C1α-mono-
adduct. A change in the positioning of its decarbamoylated
analogue DMC due to a distinct hydrogen-bonding pattern leads
to a preferred attack on the opposite face of the pyrrolidine ring
and creation of the C1β-monoadduct.
The DNA helical structure at the target CpG step appears to
be more preorganized for binding the positively charged acti-
vated MMC, and also to possess a more negative MEP in the
minor groove, when the cytosines are methylated. Both factors
acting in concert may well explain the enhanced reactivity of
MMC towards this 5MC-DNA that has been detected
experimentally.
Our unrestrained MD simulations in aqueous solution faith-
fully reproduce the drug–DNA interactions previously described
for the NMR solution structure of the major MMC–DNA
C1α-monoadduct and provide further insight into (i) the earlier
precovalent complex, (ii) the reaction of the activated monoad-
duct with a second guanine in the opposite strand at a CpG step,
and (iii) the ﬁnal ICL, which is embedded in a minimally
distorted DNA helix that does not show any appreciable curva-
ture, in good agreement with the experimental evidence.33 We
then studied in a similar way the formation of the major
DMC–DNA monoadduct with opposite stereochemistry at C1
and its stepwise evolution to an ICL. The three-dimensional
structures of these C1β-adducts have not been reported before, to
the best of our knowledge, and they were found to display some
distinct features. Most notably, the drug-bonded CpG step is
severely distorted in the β-ICL and the helix is bent towards the
minor groove.
The differences we have detected in the conformations of
these adducts, which appear in different proportions in the DNA
of cells that have been exposed to either MMC or DMC, are
likely to pose dissimilar challenges to the DNA repair machi-
neries. This may account for the experimental ﬁndings that FA
cells are hypersensitive to MMC but have normal sensitivity to
DMC whereas in other cell types DMC is more cytotoxic than
MMC.37
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